NCT05437679View on ClinicalTrials.gov

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

TerminatedOBSERVATIONAL
Enrollment

9

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
High Risk Prostate CarcinomaBiochemically Recurrent Prostate CarcinomaCastration-resistant Prostate CancerProstate Cancer
Interventions
OTHER

Blood collection

Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.

Trial Locations (2)

19004

MidLantic Urology, Bala-Cynwyd

19464

MidLantic Urology, Pottstown

Sponsors

Lead Sponsor

Angle plc
All Listed Sponsors
collaborator

MidLantic Urology, LLC

UNKNOWN

lead

Angle plc

INDUSTRY

NCT05437679 - Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System | Biotech Hunter | Biotech Hunter